|
|
News
Edinburgh Instruments
offers new Miniature Spectrometer Range from Stellarnet Inc
Press Release July 2009
Edinburgh Instruments Ltd is pleased to announce it is the
official UK and EIRE distributor for a new range of
miniature fibre optic spectrometers from Stellarnet Inc (www.stellarnet.us).
These low cost, miniature spectrometers can be used in the
laboratory or in the field due to their compact and rugged
design. The systems come with no moving parts making them
ideal for use in outdoor environments. The miniature
spectrometers can be used for standard spectrochemistry,
fluorescence experiments, spectroradiometry as well as
colour measurements. The spectrometers can be configured for
work in the UV-VIS to the NIR (2.3micron).With wide use in
academic as well as industrial settings these spectrometers
offer a low cost solution for many applications.
For more information please contact
Edinburgh Instruments Ltd for further information
Sales
Edinburgh Instruments
makes first sale of product using technology developed in
ITI Life Sciences programme
Press Release June 2008
Dundee and Edinburgh, Scotland, ITI Life Sciences,
the publicly funded innovation group, is pleased to announce
that Edinburgh Instruments, one of its earliest commercial
partners, has made its first sale of a new product called
NanoTaurus containing technology developed in an ITI R&D
programme. Edinburgh Instruments (EI) has combined novel
fluorescence technology with state-of-the-art optics and
detection in the NanoTaurus, which features the highest
sensitivity and discrimination for drug discovery screening
and assay development.
ITI Scotland owns rights to certain core elements of the
technology and associated intellectual property used in the
NanoTaurus, which were developed during a 17-month ITI
programme that ended in June 2006. Edinburgh Instruments
licensed this technology in February 2007 and the product
sale, which was made to an undisclosed Switzerland-based
pharmaceutical company, triggers a royalty payment to ITI
Scotland.
Eleanor Mitchell, Managing Director of ITI Life Sciences,
said: The sale of the NanoTaurus instrument represents an
important milestone for ITI Life Sciences as it demonstrates
for the first time a completed cycle of the ITI model: an
opportunity in cell screening was identified, from which an
ITI research programme was developed and valuable
intellectual assets resulted. These assets were licensed out
and further developed through commercial research into a
product, the sale of which generates a royalty stream back
into ITI Scotland. The process makes use of research
expertise and business skills resident in Scotland and
indicates the future potential value that can be created by
the ITI model. While these first royalties are modest they
represent a significant achievement by Edinburgh Instruments
and we are confident that ITI can repeat this success with
technologies developed in our other programmes.
Professor Des Smith, FRS, Chairman and CEO of Edinburgh
Instruments, said: We are very pleased to have made this
first important sale to a major international pharmaceutical
company and continue to market the capabilities of the
technology widely to academia and industry. The NanoTaurus
is being used in an ongoing research project with Dundee
University to create protein kinase assays without the use
of radioactive markers, producing advantages in speed, cost,
processing steps, safety and waste disposal. We are also
working with Edinburgh University to detect single base
mutations in a DNA nanoswitch, which will have potential
applications in immunoassay development and clinical
diagnostics ultimately revealing fundamentals of gene
selection.
-ends-
|
